TY - JOUR
T1 - Recombinant human growth hormone in abstinent androgenic-anabolic steroid use: Psychological, endocrine and trophic factor effects
AU - Graham, Michael R.
AU - Davies, Bruce
AU - Kieman, Andrew
AU - Cowan, David
AU - Hullin, David
AU - Baker, Julien S.
PY - 2007/2
Y1 - 2007/2
N2 - This stud), examined whether six days recombinant human growth hormone (rhGH) affected psychological profile in an abstinent androgenic-anabolic steroid (AAS) abusing group, compared with an abstinent AAS control group. Male subjects (n = 48) were assigned in a random fashion into one of two groups: (1): (n=24) control group (C): (2): (n=24) rhGH group (GH). A hospital anxiety scale (HADS) questionnaire was completed by all subjects. Physiological responses investigated included anthropometry. Biochemical markers examined included;, serum glucose, sodium, urea, lipid profile, high sensitivity C-reactive protein (hsCRP), homocysteine (I-ICY), tetra-iodothyronine (T-4), thyroid stimulating (TSH), luteinising (1,14) and follicle stimulating (FSH) hormones, testosterone (T), prolactin (PRL), cortisol and insulin like growth factor-1 (IGF-1). HADS questionnaire significantly decreased in both anxiety (A) and depression (D) symptoms within GH (P < 0.017) and compared with C(P < 0.05). Body mass index (BMI) and fat-free mass index (FFM1) significantly increased (both P < 0.017) while body fat significantly decreased within GH (P < 0.017). IGF-1 significantly increased within GH (P < 0.017) and significantly increased compared with C (P < 0.05). Serum sodium significantly increased (P < 0.017) and serum HCY, hsCRP, TSH and T4, significantly decreased within GH (all P < 0.017). PRL significantly increased and T4 significantly decreased compared with C (both P < 0.05). The findings of this study suggest that short term use of rhGH has beneficial effects on mental state in individuals who were previous abusers of AAS and appeared to have a beneficial effect on caidiovascular risk markers associated with adverse mental health.
AB - This stud), examined whether six days recombinant human growth hormone (rhGH) affected psychological profile in an abstinent androgenic-anabolic steroid (AAS) abusing group, compared with an abstinent AAS control group. Male subjects (n = 48) were assigned in a random fashion into one of two groups: (1): (n=24) control group (C): (2): (n=24) rhGH group (GH). A hospital anxiety scale (HADS) questionnaire was completed by all subjects. Physiological responses investigated included anthropometry. Biochemical markers examined included;, serum glucose, sodium, urea, lipid profile, high sensitivity C-reactive protein (hsCRP), homocysteine (I-ICY), tetra-iodothyronine (T-4), thyroid stimulating (TSH), luteinising (1,14) and follicle stimulating (FSH) hormones, testosterone (T), prolactin (PRL), cortisol and insulin like growth factor-1 (IGF-1). HADS questionnaire significantly decreased in both anxiety (A) and depression (D) symptoms within GH (P < 0.017) and compared with C(P < 0.05). Body mass index (BMI) and fat-free mass index (FFM1) significantly increased (both P < 0.017) while body fat significantly decreased within GH (P < 0.017). IGF-1 significantly increased within GH (P < 0.017) and significantly increased compared with C (P < 0.05). Serum sodium significantly increased (P < 0.017) and serum HCY, hsCRP, TSH and T4, significantly decreased within GH (all P < 0.017). PRL significantly increased and T4 significantly decreased compared with C (both P < 0.05). The findings of this study suggest that short term use of rhGH has beneficial effects on mental state in individuals who were previous abusers of AAS and appeared to have a beneficial effect on caidiovascular risk markers associated with adverse mental health.
U2 - 10.2174/156720207779940699
DO - 10.2174/156720207779940699
M3 - Article
SN - 1567-2026
VL - 4
SP - 9
EP - 18
JO - CURRENT NEUROVASCULAR RESEARCH
JF - CURRENT NEUROVASCULAR RESEARCH
IS - 1
ER -
